Hoth Therapeutics (HOTH) Pops After Announcing Upbeat Clinical Data

The eagerness among investors with regards to companies working on COVID-19 treatments continues to be a theme and hence, the Hoth Therapeutics (NASDAQ: HOTH) stock was in sharp focus yesterday.

On Tuesday, the company announced positive preclinical results with regards to its treatment for COVID 19. Following the announcement, the stock surged by as high as 15% as investors piled onto the stock. The announcement was related to the company’s peptide treatment named HT 002.

Hoth announced that the product managed to curtail the cytopathic effect of COVID 19 by as big as 50% and that was a considerably positive development. On the other hand, it is also necessary to point out that HT 002 did not display the presence of any cytotoxicity. It is positive since the absence of cytotoxicity implies that the product could act as a COVID 19 therapy at a range of dilutions. It now remains to be seen if the HOTH stock can record further gains today.

Asan Abdiev

CEO and Editor in Chief. Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life